一种用于克服非小细胞肺癌治疗中抗原异质性的多靶向 CAR-T 细胞平台
A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer.
这些发现支持采用多靶点CAR-T 策略来应对NSCLC及可能其他实体瘤中的抗原异质性。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
通过生物信息学分析和实验验证揭示组织驻留记忆 T 细胞在肺腺癌中的意义
英文原题：Revealing the significance of tissue-resident memory T cells in lung adenocarcinoma through bioinformatic analysis and experimental validation.
查看英文原题
Revealing the significance of tissue-resident memory T cells in lung adenocarcinoma through bioinformatic analysis and experimental validation.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
肺 T RM 细胞相关预后特征是一种预测 LUAD 患者预后和治疗结果的有效工具。
研究思路结论见上方概要
目的
探讨肺 TRM 细胞在肺腺癌（LUAD）发生发展和治疗中的功能。
方法
应用R语言生物信息学分析获得差异表达（DE）的肺TRM细胞特异性基因及相关预后特征，并通过外部数据集、免疫组化染色图像和生物学实验进一步验证。
结果
共鉴定出130个DE肺T RM细胞特异性基因，其中14个参与预后特征，包括SLC16A3、ARHGAP11A、PTTG1、DTL、GPRIN1、EXO1、GAPDH、TYMS、DAPK2、CCL20、HLA-DQA1、ADAM12、ALOX5AP和OASL。该特征在预测LUAD患者的总生存期和抗PD-1/PD-L1免疫治疗结局方面高效且稳健。在训练队列中，预测1年、3年和5年生存率的AUC分别为0.688、0.698和0.648，在验证队列中分别为0.867、0.662和0.672。该特征对患者对化学药物的敏感性也具有预测价值。TYMS是预后特征中的枢纽基因，在实验验证中与LUAD进展和细胞增殖密切相关。
展开英文摘要原文
PURPOSE
To investigate the functions of lung T RM cells in the development and treatment of lung adenocarcinoma (LUAD).
METHODS
R-language bioinformatics analysis was applied to obtain differentially expressed (DE) lung T RM cell-specific genes and a related prognostic signature, which were further validated using external datasets, immunohistochemical staining images, and biological experiments.
RESULTS
A total of 130 DE lung T RM cell-specific genes were identified, 14 of which were involved in the prognostic signature, including SLC16A3 , ARHGAP11A , PTTG1 , DTL , GPRIN1 , EXO1 , GAPDH , TYMS , DAPK2 , CCL20 , HLA-DQA1 , ADAM12 , ALOX5AP and OASL . The signature was efficient and robust in predicting the overall survival and anti-PD-1/PD-L1 immunotherapeutic outcomes of patients with LUAD. The AUCs for predicting the 1-, 3-, and 5-year survival rates were 0.688, 0.698, and 0.648, respectively, in the training cohort, and were 0.867, 0.662, and 0.672, respectively, in the validation cohort. The signature also had predictive value for the sensitivity of patients to chemical drugs. TYMS was a hub gene in the prognostic signature, and was strongly associated with LUAD progression and cell proliferation in the experimental validation.
CONCLUSIONS
The lung T RM cell-related prognostic signature is an effective tool for predicting the prognosis and therapeutic outcomes of patients with LUAD.
论文信息
- 作者
- Li Z、Tian M、Yang Y、Wang Y、Zhang L、Huang F、Wen X、Yin X
- 单位
- Department of Radiotherapy Oncology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China.China
- 期刊
- Frontiers in immunology2025
- 原文标识
- PubMed 40642061 · DOI 10.3389/fimmu.2025.1600863
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →